---
title: "Hemodialysis-linked shifts in plasma N‑glycan profiles suggest anti‑inflammatory signatures"
id: "frontiers-in-immunology-15-hemodialysis-is-associated-with-changes-in-plasma-protein-n-glycan-profile"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-hemodialysis-is-associated-with-changes-in-plasma-protein-n-glycan-profile"
content_type: "clinical_feed_article"
specialty: "Nephrology"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1840036"
published_at: "2026-11-11T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Hemodialysis-linked shifts in plasma N‑glycan profiles suggest anti‑inflammatory signatures
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-hemodialysis-is-associated-with-changes-in-plasma-protein-n-glycan-profile
- **Specialty:** [Nephrology](https://medichelpline.com/clinical-feed/nephrology.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1840036)
- **Published At:** 2026-11-11T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators reported that **hemodialysis** is associated with measurable changes in the plasma protein **N-glycan** profile in the study cohort. - The authors interpreted these glycan pattern shifts as potentially promoting **anti-inflammatory** traits in circulating proteins; language in the source framed this as a possible effect rather than a proven mechanism. - The article identified specific directional changes in glycan features; the source did not provide numerical effect sizes, p-values, or absolute concentration changes in the accessible text. - The team linked glycosylation alterations to functional implications for inflammatory modulation, but causal relationships were not claimed. - The source did not report complete methodological details in the excerpt available here: sample size, dialysis modality/subtype, timing of sampling relative to dialysis, or analytical platforms were not provided. - The authors noted interpretive limits arising from observational association; they did not present interventional data demonstrating clinical outcome effects. - Key unanswered questions remain: whether glycan shifts are transient or persistent, whether they vary by dialysis prescription, and whether they alter infection risk or vaccine responses in patients on **hemodialysis**. - The accessible text did not include demographic breakdowns, comorbidity data, or adjustments for confounders; these elements are necessary to assess generalizability and were not shown in the source content provided.
## Clinical Analysis & Structured Key Points
Frontiers | Hemodialysis is associated with changes in plasma protein N-glycan profile: possibly promoting expression of anti-inflammatory traits ORIGINAL RESEARCH article Front. Immunol. , 11 November 2026 Sec. Inflammation Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1840036 Published in Frontiers in Immunology Inflammation 7 impact factor 11.3 citescore Part of a Research Topic Nutritional and Metabolic Landscape in CKD and ESKD: Mechanisms, Biomarkers, and Integrative Management Submission open 16k views 14 articles Editor & Reviewers Edited by G C Guoyun Chen Reviewed by M T María Teresa Hernández-Huerta M P Martin Pejchinovski Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Table 1 Characteristics of patients included in the analysis (n = 54). View in article Table 2 Plasma protein derived N-glycan traits calculated out of 39 directly measured total plasma protein N-glycan peaks. View in article Table 3 Longitudinal changes in IgG and plasma glycan traits after haemodialysis. View in article ORIGINAL RESEARCH article Front. Immunol. , 11 November 2026 Sec. Inflammation Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1840036 Hemodialysis is associated with changes in plasma protein N-glycan profile: possibly promoting expression of anti-inflammatory traits I D Ivan Durlen 1 † M C Matija Crnogorac 1 † * B R Barbara Radovani Trbojevic 2 D V David Visentin 3 I G Ivan Gudelj 4 I H Irzal Hadzibegovic 5 G L Goran Lauc 2,4 L Z Lada Zibar 6,7 1. Department of Nephrology and Dialysis, Dubrava University Hospital, Zagreb, Croatia 2. Genos Glycoscience Research Laboratory, Zagreb, Croatia 3. Faculty of Biotechnology and Drug Development, University of Rijeka, Rijeka, Croatia 4. Faculty of Pharmacy and Biochemistry , University of Zagreb, Zagreb, Croatia 5. Department of Cardiovascular Medicine, Dubrava University Hospital, Zagreb, Croatia 6. Department for Nephrology, University Hospital Merkur, Zagreb, Croatia 7. Josip Juraj Strossmayer University of Osijek, School of Medicine, Osijek, Croatia See more Article metrics View details Abstract Introduction: Biomarkers capable of predicting outcomes in patients undergoing hemodialysis (HD) remain limited. N-glycosylation of plasma proteins plays an important role in numerous biological processes, including immune regulation and inflammation. Alterations in N-glycan profiles have been described in several diseases, including chronic kidney disease (CKD). However, studies investigating N-glycosylation in dialysis patients are scarce, particularly in those receiving hemodialysis. Patients and methods: We included 55 patients undergoing chronic hemodialysis who provided informed consent. Demographic data, comorbidities, and dialysis-related parameters were collected. Along with C-reactive protein analyses, the N-glycan profile of total plasma proteins was measured before hemodialysis, immediately after the procedure, and 24 hours later. Measurements were performed before the first dialysis session of the week, following the longest interdialytic interval (three days). C-reactive protein (CRP) was measured using immunoturbidimetry. Total plasma protein N-glycan profiles were analyzed using ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR). Results: Our study showed that in our patient cohort, sialylsation and fucosylation, as previously published data in which these traits are associated with proinflammatory milleu in various diseases/conditions, are proinflammatory traits in total plasma proteins N-glycosylation profile. Our findings demonstrate that hemodialysis itself possibly reduces pro-inflammatory glycosylation patterns, independently of changes in CRP levels. These results suggest that hemodialysis may exert biological effects beyond the removal of excess fluid and uremic toxins. Conclusion: Hemodialysis may have a measurable anti-inflammatory effect in patients undergoing chronic treatment. Changes in the N-glycosylation profile of total plasma proteins may represent potential biomarkers for assessing hemodialysis effectiveness and predicting clinical outcomes in HD patients. Introduction Glycosylation plays an important role in many chronic diseases. In cardiovascular diseases, it modulates processes including endothelial function and inflammation ( 1 ). Changes in N-glycan branching, sialylation, and fucosylation, have been linked to atherosclerosis, arterial hypertension, and myocardial infarction ( 2 , 3 ). Glycosylation, thus, serves as an important regulator of vascular homeostasis and immune balance, and is important in the pathogenesis of cardiovascular diseases. The role of glycosylation has been an area of interest in autoimmune diseases, including rheumatoid arthritis, systematic lupus erythematosus (SLE), and inflammatory bowel disease. Despite advances in understanding of these diseases, the multifactorial etiology involving genetic predispositions, environmental triggers and immunological imbalance still make both diagnosis, treatment and follow-up difficult ( 4 – 8 ). Glycosylation of IgG has been identified as an indicator of disease progression and immune dysregulation. Compared to healthy controls, rheumatoid arthritis patients had characteristic glycosylation patterns, i.e., decreased galactosylation, decreased sialylation, and increased IgG fucosylation ( 9 , 10 ). In recent ultra-performance LC analysis, reduced galactosylation, reduced sialylation, reduced core fucosylation, and elevated bisecting N-acetylglucosamine (GlcNAc) were detected in SLE patients compared to healthy controls ( 11 ). Reduced sialylation is known to negatively affect the anti-inflammatory function of IgG, promoting immune-complex promotion. Decreased core fucosylation increases antibody-dependent cellular cytotoxicity, which increases organ damage ( 12 , 13 ). According to the literature sialylation and fucosylation of plasma proteins heavily modulate systemic inflammation, acting as crucial functional switches that either propagate or resolve the immune response. During an acute-phase response or chronic inflammatory conditions, the total plasma N-glycome undergoes rapid structural alterations. While specific glycosylation patterns like antennary fucosylation and increased branch sialylation directly drive proinflammatory cascades, other forms—such as core fucosylation and IgG Fc-terminal sialylation—serve as counterbalancing, anti-inflammatory mechanisms ( 14 , 15 ). Protein glycosylation is associated with many renal diseases and dysregulated glycosylation of proteins has been implicated in various glomerular and non-glomerular renal diseases ( 16 ). While alterations in systemic N-glycan profiles have been documented across chronic kidney diseases (CKD), it is vital to distinguish between specific glyco-phenomena. For instance, aberrant O-glycosylation of IgA1 drives IgA nephropathy ( 17 ), and hyperglycemia-induced intracellular O-GlcNAcylation regulates diabetic nephropathy progression ( 18 ). These localized mechanisms are biochemically distinct from the systemic N-glycosylation modifications seen in circulating plasma glycoproteins, which act as functional switches modulating the vascular and immune systems ( 14 , 15 ). Recent literature highlights the powerful role of systemic glycan profiles as biomarkers for clinical endpoints. Notably, a recent 2026 large-scale study established that distinct IgG N-glycan traits are directly associated with long-term adverse outcomes and mortality risk in advanced CKD populations ( 19 ). Furthermore, systemic glycosylation profiles have been shown to react rapidly to acute procedural or inflammatory stresses, shifting significantly within hours following surgical or acute immune events ( 20 ). Despite these insights, longitudinal tracking of total plasma vs. IgG-specific glycan adaptations immediately surrounding an active extracorporeal procedure like a hemodialysis session remains uncharacterized. This study attempts to addresses this knowledge gap”. In systemic lupus erythematosus, data from the studies show the importance of abnormal protein glycosylation in the development of lupus nephritis. IgG glycosylation appears to be directly involved in regulating nephritis progression. Reduction in sialylation and galactosylation of IgG N-glycans is associated with progressive renal fibrosis progression through increasing inflammation ( 21 ). Hemodialysis is a method that removes metabolic waste products, excess water, and toxins from the blood and restores electrolyte balance using an extracorporeal blood circuit and a semipermeable membrane ( 22 ). Core physical principles of hemodialysis include: diffusion i.e. small waste products (like urea and creatinine) move passively from an area of high concentration in the blood to a lower concentration in the dialysate fluid across a semipermeable membrane, ultrafiltration i.e. excess water is removed by applying a hydrostatic trans-membrane pressure gradient from the blood compartment into the dialysate, convection i.e. solutes dissolved in water are dragged across the semipermeable membrane alongside water under hydrostatic pressure, which helps clear larger molecules and countercurrent flow meaning blood and dialysate flow in opposite directions inside the dialyzer to maintain a maximal concentration gradient along the entire length of the membrane ( 22 ). Key technical components of the system are the filter i.e. a cartridge containing numerous tiny hollow-fiber semipermeable membranes where blood flows inside the fibers and dialysate flows on the outside and dialysate which is a electrolyte solution that resembles normal extracellular fluid (plasma), designed to help remove toxins and excess electrolytes such as potassium ( 22 ). Hemodialysis patients have a 20 times higher risk for cardiovascular disease than the healthy population ( 16 ) as well as increased mortality rates ( 17 , 18 ). Apart from the usual prognostic risk factors in the general population, such as age, diabetes mellitus and arterial hypertension, there are also specific end-stage renal disease (ESRD) associated risk factors such as anemia, endothelial dysfunction ( 23 ), increased oxidative stress ( 24 ) and chronic inflammation ( 25 ) to name a few. Chronic inflammation in ESRD has been shown to increase both cardiovascular and total mortality risk ( 21 , 26 – 28 ). There are even methods, such as hemoperfusion, that are based on adsorption, to remove proinflammatory molecules ( 29 ). Biomarkers to predict the outcomes of hemodialysis patients are limited. N-glycosylation plays an important role in various biological functions. The role of glycosylation has been well examined in numerous diseases ( 11 – 15 , 18 – 22 ) including, though in a limited fashion, chronic kidney disease (CKD), in particular one attributed to DM ( 30 – 32 );. Changes in total plasma protein N-glycan profile as a marker for a predictor of prognosis have been studied in a few peritoneal dialysis patients ( 33 – 35 ) and, to the best of our knowledge, only one study on hemodialysis patients ( 36 ). That study demonstrated that specific serum N-glycans were associated with the prognosis in hemodialysis patients, suggesting potential clinical relevance of glycan profiling in this population. In this study, we analyzed changes in the total plasma protein N-glycosylation profile before and after hemodialysis session and correlation with markers of inflammation and ESRD-specific risk factors. Patients and methods Study population This was a single-center, prospective, longitudinal observational study conducted at Dubrava University hospital, Zagreb. Croatia. All the patients within our dialysis department who signed the ICF were recruited (N = 55). All the first measurements were performed on the same two days (Monday and Tuesday, May 2024.), before the first hemodialysis session of the week, corresponding to the longest inter-dialytic interval of three days. All the patients had 3 measurements (before and after the first weekly HD session, and 24 hours after the session). The patients both on HD and HDF were included, using the regular filter size and type the patient uses. UF rates, weight changes and medications administered were not included in the analysis, but we think that this does not affect the changes. Assuming an effect size of 0.40, an alpha error of 0.1, and a power of 0.9, the estimated sample size to demonstrate the significance of changes is 42. Most similar studies evaluating acute changes in the N-glycan profile of total plasma proteins and IgG included around 30 participants. Demographic and clinical data were collected, including comorbidities and dialysis-related parameters. Eligible participants were adults older than 18 years who had been receiving chronic hemodialysis for at least one month prior to enrollment. Patients with acute medical conditions, including infectious or non-infectious inflammatory diseases that could potentially influence the study results, as well as those with active malignant disease, were excluded from the study. Methods In addition to demographic and clinical data, including body mass index (BMI) and blood pressure, C-reactive protein (CRP) was measured as a marker of inflammation. The N-glycan profile of total plasma proteins was analyzed at three time points: immediately before the hemodialysis session, immediately after completion of the procedure, and 24 hours following hemodialysis. All measurements were performed before the first hemodialysis session of the week, corresponding to the longest inter-dialytic interval of three days. CRP concentrations were determined using an immunoturbidimetric assay. The study included 55 patients undergoing chronic hemodialysis. One participant exhibiting an extreme longitudinal glycan trajectory was excluded as a multivariate outlier ( Supplementary Figure 2 ), resulting in a final analytical cohort of 54 patients, of whom 18 (33.3%) were female. The mean age of the study population was 68 (SD 12.86) with the median duration of hemodialysis treatment of 7.39 years. End-stage renal disease (ESRD) was most attributed to type 2 diabetes mellitus and arterial hypertension ( Table 1 ). Table 1 Patients’ characteristics Patient cohort (N = 54) Age (years) 68 (SD 12.86) Sex, Males N (%) 36 (66%) BMI (kg/m2) 26.61 (SD 4.89) Type 2 diabetes N(%) 27 (89) Arterial hypertension N(%) 50 (92) Cardiovascular disease N(%) 21 (38) SCr predialytic (μmol/l) 809 (IQR 642.75 - 1017.50) SCr postidialytic (μmol/l) 267 (IQR 209.00 - 343.00) Time on dialysis (years) 3.0 (IQR 2 - 5) Hemoglobin (g/l) 108 (IQR 101.00 - 111.50) Serum albumin (g/l) 37 (IQR 35.00 - 39.00) Total serum protein (g/l) 66.5 (IQR 63.00 - 69.00) CRP (mmol/l) 8.56 (15.76) Ferritin (mmol/l) 199.5 (IQR 93.25 - 328.75) Interdialytic weight gain (kg) 2.9 (IQR 1.50 - 3.60) Survived at 30 months N(%) 34 (63.0) Causes of CKD/ESRD N(%) T2DM N(%) 11 (20%) AH N(%) 13 (24%) T2DM+AH N(%) 13 (24%) GN N(%) 5 (9%) Others (ADPKD, VUR, infections … etc.) N(%) 12 (23%) Characteristics of patients included in the analysis (n = 54). BMI, body mass index; SCr, serum creatinine; CKD, chronic kidney disease; ESRD, end stage renal disease; CRP, C-reactive protein; T2DM, type 2 diabetes mellitus; AH, arterial hypertension; GN, glomerulonephritis; ADPKD, adult polycystic kidney disease; VUR, vesico-ureteral reflux. Enzymatic release, labeling, and purification of total plasma protein N-glycans De-glycosylation of total plasma proteins was performed. Prior to de-glycosylation, thawed plasma samples were vortexed and centrifuged. Directly after the centrifuge, EDTA plasma was stored at -20 °C until it was analysed (only one thaw cycle). Plasma proteins were denatured by addition of sodium dodecyl sulfate (SDS) and incubation at 65 °C. The excess of SDS was neutralized with Igepal-CA630 (Sigma-Aldrich, USA). N-glycans were released from the backbone of plasma proteins by incubation at 37 °C after the addition of PNGase F (Promega, USA). The released plasma protein N-glycans were subsequently labeled with fluorescent dye 2-aminobenzamide (2-AB). Released and fluorescently labeled plasma N-glycans were purified from proteins, excess dye and other reagents using solid phase extraction (SPE). For the SPE step, an Acroprepadv 1 mL 0.2 μm wwPTFE plate (Pall) was used as stationary phase. The labelled N-glycans were eluted with ultrapure water (> 18 Ω) and stored at -20 °C until use. HILIC-UHPLC-FLR analysis of 2-AB labeled total plasma protein N-glycans. Fluorescently labeled N-glycans were analyzed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR) on a Waters Acquity UPLC H-class instrument. Samples were kept at 10 °C before injection, and the separation temperature was 25 °C. Chromatographic separation of glycan structures was performed on Waters UPLC Glycan bridged ethylene hybrid (BEH) amide chromatographic columns (130 Å, 1.7 μm BEH particles, 2.1 × 150 mm). Solvent A was 100 mM ammonium formate, pH 4.4, while solvent B was LC-MS grade acetonitrile (ACN). Separation was performed with a linear gradient of 70-53% solvent B at a flow rate of 0.56 ml/min in a 25-minute analytical run. Excitation and emission wavelengths were set at 250 and 428 nm, respectively. Each chromatogram was separated into 39 glycan peaks (GP1-GP39) and the amount of glycans in each peak was expressed as a percentage of the total integrated area ( Figure 1 ). Based on the similar structural features of the analyzed glycans, 16 additional derived glycan traits were calculated for total plasma protein N-glycome according to the formulas shown in Table 2 . Figure 1 Representative chromatogram of 2-AB labelled plasma protein N-glycans separated by HILIC–UHPLC-FLR. The integration areas, together with a major structure presented in each glycan peak are given. Glycan peaks are numbered as used in the paper. Table 2 Derived trait Formula Low branching (mono- and biantennary glycans) LB SUM(GP1 + GP2 + GP3 + GP4 + GP5 + GP6 + GP8 + GP9 + GP10 + GP11 + 0.5xGP12 + GP13 + GP14 + GP15 + GP16 + GP17 + GP18 + GP20 + GP21 + GP22 + GP23)/GP total * 100 High branching (tri- and tetraantennary glycans) HB SUM(GP24 + GP25 + GP26 + GP27 + GP28 + GP29 + GP30 + GP31 + GP32 + GP33 + GP34 + GP35 + GP36 + GP37 + GP38 + GP39)/GP total * 100 Agalactosylation (G0) SUM(GP1 + GP2)/GPtotal * 100 Monogalactosylation (G1) SUM(GP3 + GP4 + GP5 + GP6 + GP13)/GP total * 100 Digalactosylation (G2) SUM(GP8 + GP9 + GP10 + GP11 + 0.5xGP12 + GP14 + GP15 + GP16 + GP17 + GP18 + GP20 + GP21 + GP22 + GP23)/GPtotal * 100 Trigalactosylation (G3) SUM(GP24 + GP25 + GP26 + GP27 + GP28 + GP29 + GP30 + GP31 + GP32 + GP33 + GP34 + GP35)/GP total * 100 Tetragalactosylation (G4) SUM(GP36 + GP37 + GP38 + GP39)/GP total * 100 Neutral glycans (S0) SUM(GP1 + GP2 + GP3 + GP4 + GP5 + GP6 + GP8 + GP9 + GP10 + GP11)/GP total * 100 Monosialylation (S1) SUM(0.5xGP12 + GP13 + GP14 + GP15 + GP16 + GP17)/GP total * 100 Disialylation (S2) SUM(GP18 + GP20 + GP21 + GP22 + GP23 + GP24 + GP25 + GP26 + GP27)/GP total * 100 Trisialylation (S3) SUM(GP28 + GP29 + GP30 + GP31 + GP32 + GP33 + GP34 + GP35 + GP36)/GP total * 100 Tetrasialylation (S4) SUM(GP37 + GP38 + GP39)/GP total * 100 Incidence of bisecting GlcNAc (B) SUM(GP2+GP3+GP6+GP9+GP11+GP15+GP17+GP23)/GP total * 100 Antennary fucosylation (AF) SUM(GP27+GP33+GP35+GP39)/GP total * 100 Core fucosylation (CF) SUM(GP1 + GP2 + GP4 + GP5 + GP6 + GP10 + GP11 + GP13 + GP16 + GP17 + GP22 + GP23 + GP31 + GP34 + GP35)/GP total * 100 High mannose structures (HM) SUM(GP7 + 0.5xGP12 + GP19)/GP total * 100 Plasma protein derived N-glycan traits calculated out of 39 directly measured total plasma protein N-glycan peaks. HILIC-UHPLC-FLR detection IgG N-glycan analysis The analys
## Related Clinical Research

- [Cardiovascular risk and mortality after statin initiation: achieved LDL and non‑HDL levels in a 3‑](https://medichelpline.com/clinical-feed/plos-medicine-0-risk-of-cardiovascular-events-and-mortality-associated-with-ldl-and-non-hdl.md)
- [Comparing BMI, Waist Circumference, and BRI for Predicting ASCVD, AF, and Mortality in 1.2M Koreans](https://medichelpline.com/clinical-feed/plos-one-14-prognostic-associations-of-anthropometric-indices-with-major-health-outcomes-a.md)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)
- [SGLT2 Inhibitors and Rheumatoid Arthritis Risk in Type 2 Diabetes: Summary of Reported Emulated Ta](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-the-association-between-sglt2-inhibitors-and-rheumatoid-arthritis-risk-in-type.md)
- [CXCL10 rs8878 genotype associates with preserved T cells and 30‑day survival in sepsis](https://medichelpline.com/clinical-feed/frontiers-in-immunology-1-cxcl10-rs8878-identifies-a-genotype-associated-immune-phenotype-linked-to-t.md)

## Navigation
- [← Back to Nephrology Feed](https://medichelpline.com/clinical-feed/nephrology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.